BRIEF—Galen adds Provocholine to product portfolio

Privately-owned pharma company Galen has acquired the rights to Provocholine 100mg Powder for nebuliser solution (methacholine chloride)⁠ - manufactured by Methapharm Specialty Pharmaceuticals of Canada - to exclusively distribute and commercialize in the UK.

This product is used by healthcare specialists in patients aged 17 and over to detect bronchial airway hyperreactivity, to assist in the diagnosis of asthma.

Galen, a subsidiary of Northern Ireland’s Almac Group, which has successfully launched more than 100 products in more than 25 locations across the world in a range of areas including medical nutrition, pain management, dermatology and gastroenterology, has developed a global expansion strategy of its product portfolio.

This partnership extends the company’s UK offering to more treatment areas, now including respiratory disease.